DIAVERIDINE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H16N4O2
Molecular Weight	260.2917
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=C(OC)C=C(CC2=C(N)N=C(N)N=C2)C=C1

InChI

InChIKey=LDBTVAXGKYIFHO-UHFFFAOYSA-N

InChI=1S/C13H16N4O2/c1-18-10-4-3-8(6-11(10)19-2)5-9-7-16-13(15)17-12(9)14/h3-4,6-7H,5H2,1-2H3,(H4,14,15,16,17)

HIDE SMILES / InChI

Description
Sources: https://www.drugs.com/international/diaveridine.html | https://www.ncbi.nlm.nih.gov/pubmed/3258144 | https://www.ncbi.nlm.nih.gov/pubmed/21781790 | http://www.avico.com.jo/ct-menu-item-17/ct-menu-item-155/ct-menu-item-215/ct-menu-item-237.html | https://www.ncbi.nlm.nih.gov/pubmed/1906236

Diaveridine is an antiprotozoal agent. It inhibits dihydrofolate reductase activity. Diaveridine is genotoxic to mammalian cells in vitro and in vivo. In veterinary it is used for the treatment of coccidiosis. It was reported that EGIS-5645 (considered to be diaveridine) exerts anti-inflammatory properties.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
dihydrofolate reductase activity 1 Target ID: GO:0004146 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3258144 \| https://www.ncbi.nlm.nih.gov/pubmed/4591806	Inhibitor 8504
inflammatory response 47 Target ID: GO:0006954 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1906236	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Coccidiosis 45 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4591806 https://www.drugs.com/international/diaveridine.html	Curative		Approved 8583	VERICOX Approved Use VERICOX is indicated for the treatment of coccidial intestinal and cecal infection in poultry
Inflammation 105 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1906236 http://adisinsight.springer.com/drugs/800002763	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
In-vitro activity of lytic peptides alone and in combination with macrolides and inhibitors of dihydrofolate reductase against Pneumocystis carinii.	1998-10	9818742
Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro.	1996-12	9039272
Fine structural specificity differences of trimethoprim allergenic determinants.	1996-10	8911701
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.	1992-09	1416885
[Synthesis and antimycobacterial action of lipophilic substituted 2,4-diamino-5-benzylpyrimidines].	1988-12	3149896
5-BENZYL-2,4-DIAMINOPYRIMIDINES AS ANTIBACTERIAL AGENTS. I. SYNTHESIS AND ANTIBACTERIAL ACTIVITY IN VITRO.	1962-11	14056446

Patents

Sample Use Guides

In Vivo Use Guide

VERICOX (1 g of water-soluble powder for oral use containing Sulphaquinoxaline Sodium 200 mg, Sulphadimidine sodium 250 mg, Diaveridine 50 mg, Vit. K3 20 mg) for the treatment of intestinal and cecal infection in poultry: broilers, turkeys: 1 gm per 2 liters of drinking water for 5-7 days.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

DIAVERIDINE

Official Name

English

BW 49-210

Preferred Name

English

DIAVERIDINE [MI]

Common Name

English

NSC-408735

Code

English

DIAVERIDINE [USP-RS]

Common Name

English

2,4-Diamino-5-veratrylpyrimidine

Systematic Name

English

DIAVERIDINE [MART.]

Common Name

English

BW-49210

Code

English

DIAVERIDINE [USAN]

Common Name

English

2,4-PYRIMIDINEDIAMINE, 5-((3,4-DIMETHOXYPHENYL)METHYL)-

Systematic Name

English

BW-49-210

Code

English

diaveridine [INN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QP51AX18